Registered title, quoted from ClinicalTrials.gov
Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention
An open trial on lymphoma, registered on ClinicalTrials.gov. Led by Shanghai General Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06686108, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
14 years to 55 years; sex: all
Registered eligibility fields
4.For those who are resistant to BCL-2 inhibitors before transplantation, if the disease progresses during the application process, or if 3-4 courses of induction therapy containing BCL2 inhibitors do not improve.
Exclusion criterion 4
3.ECOG score is 0-2 points.
Inclusion criterion 3
4.Blood routine: ANC ≥ 1.0 × 109/L, PLT ≥ 50 × 109/L.
Inclusion criterion 4
b. Initial diagnosis of WBC ≥ 100 × 109/L.
Inclusion criterion 7
9.Blood routine: ANC<1.0 × 109/L or PLT<50 × 109/L.
Exclusion criterion 9
h. Residual lesions before transplantation: Flow cytometry analysis showed that the proportion of abnormal lymphoid cells in the bone marrow was greater than 0.01%; Positive detection of minimal residual lesions in molecular biology; PET-CT scan shows that residual lesions are still active.
Inclusion criterion 13
12.Pregnant or lactating women.
Exclusion criterion 12
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; other conditions the trial excludes.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06686108, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- 1.14-55 years old, male,or female.
- 2.Patients with allo-HSCT due to T-LBL/ALL, the donor type is not limited.
- 3.ECOG score is 0-2 points.
- 4.Blood routine: ANC ≥ 1.0 × 109/L, PLT ≥ 50 × 109/L.
- 5.One of the following high-risk factors:
- a. Age of initial diagnosis ≥ 35 years old.
- b. Initial diagnosis of WBC ≥ 100 × 109/L.
- c. Initial diagnosis of LDH exceeding the upper limit of normal values.
- d. Initial diagnosis of bone marrow involvement (blast cells ≥ 5%).
- e. Initial diagnosis of a bulky in the mediastinum (longest diameter ≥ 10cm).
- f. ETP immunophenotype.
- g. During the induction chemotherapy process, 2 courses did not achieve partial remission and/or 4 courses did not achieve complete remission.
- h. Residual lesions before transplantation: Flow cytometry analysis showed that the proportion of abnormal lymphoid cells in the bone marrow was greater than 0.01%; Positive detection of minimal residual lesions in molecular biology; PET-CT scan shows that residual lesions are still active.
- i. Based on the ELN recommendation based on adult T-ALL: gene mutations involving myeloid related genes, RAS/PI3K/AKT, JAK/STAT signaling pathway, and epigenetics, such as FLT3, NRAS/KRAS, PTEN, IL7R, JAK1, JAK3, DNMT3A, IDH1, IDH2; TP53, BCL2 mutations; t (8; 14) (q24; q11)/MYC rearrangement; t (7; 19) (q34; p13)/TCR-LYL1,TCR-MEF2C; del(5q) (q14).
- j. High risk subgroups based on NGS definition: PI3K signaling pathway/NRAS, KRAS/TP53/IKZF1/DNTM3A/IDH1, IDH2 gene mutation with or without NOTCH1, FBXW7/PHF6/EP300 gene mutation.
Exclusion Criteria:
- 1.Central involvement during any course of the disease.
- 2.Patients who have not achieved complete remission before transplantation.
- 3.Identify those with available targeted drugs.
- 4.For those who are resistant to BCL-2 inhibitors before transplantation, if the disease progresses during the application process, or if 3-4 courses of induction therapy containing BCL2 inhibitors do not improve.
- 5.Individuals who are known to be allergic to demethylating drugs or venetoclax.
- 6.Individuals with grade 2 or more degrees of active acute GVHD.
- 7.Individuals with moderate to severe chronic GVHD.
- 8.T-LBL/ALL relapse (flow cytometry abnormal lymphocyte cell proportion>0.01%, WT1 positive, fusion gene positive, or extramedullary recurrence), or transplant rejection, bone marrow donor cell chimerism<95%.
- 9.Blood routine: ANC<1.0 × 109/L or PLT<50 × 109/L.
- 10.Combined with severe organ dysfunction; The ratio of aspartate aminotransferase (AST)/alanine aminotransferase (ALT) is more than 3 times the normal value or the normal value of direct bilirubin is more than 3 times; The endogenous creatinine clearance rate (Ccr) is less than 50mL/min or 1.5 times the normal value of blood creatinine, regardless of whether hemodialysis treatment is used.
- 11.Merge severe active infections.
- 12.Pregnant or lactating women.
- 13. Accepting other investigational drugs.
- 14.According to the researchers' assessment, the patient may have complications that could lead to other dangers.
Quoted from ClinicalTrials.gov, NCT06686108, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06686108, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.